申请人:Ciba-Geigy Corporation
公开号:US04177344A1
公开(公告)日:1979-12-04
The invention relates to novel 1,6-anhydro-.beta.-D-hexopyranose derivatives of the formula I ##STR1## in which R.sub.2 is hydrogen, methyl or aromatic acyl, R.sub.3 and R.sub.4 are alkyl, alkenyl or aralkyl and one of the radicals R.sub.3 and R.sub.4 is also an aroyl radical and R.sub.4 can also be hydrogen, with the proviso that the radicals R.sub.3 and R.sub.4 together contain at least 3 carbon atoms and, if R.sub.4 is the benzyl radical, the radical R.sub.3 contains at least 2 carbon atoms, and, if one of the radicals R.sub.3 and R.sub.4 is an aroyl radical, R.sub.2 is hydrogen. These compounds especially the 1,6-anhydro-3,4-di-O-benzyl-.beta.-D-glucopyranose or the 1,6-anhydro-.beta.-D-glucopyranose, can be used as fibrinolytic agents and thrombolytic agents.
该发明涉及新型1,6-脱水-β-D-己糖衍生物的公式I##STR1##其中R.sub.2是氢、甲基或芳香酰基,R.sub.3和R.sub.4是烷基、烯基或芳基烷基,其中R.sub.3和R.sub.4中的一个基团也是芳酰基,R.sub.4也可以是氢,但要求R.sub.3和R.sub.4的基团总共含有至少3个碳原子,并且如果R.sub.4是苄基基团,则基团R.sub.3含有至少2个碳原子,如果R.sub.3和R.sub.4中的一个基团是芳酰基,则R.sub.2是氢。这些化合物,尤其是1,6-脱水-3,4-二-O-苄基-β-D-葡萄糖吡喃糖或1,6-脱水-β-D-葡萄糖吡喃糖,可以用作纤溶剂和溶栓剂。